

**2017 Mo-99 TOPICAL MEETING ON
MOLYBDENUM-99 PRODUCTION TECHNOLOGY DEVELOPMENT**

**SEPTEMBER 10-13, 2017
MONTREAL MARRIOTT CHATEAU CHAMPLAIN
MONTREAL, QC CANADA**

Establishment of LEU based Mo-99 production capacity at IRE

Valery Host
Research and Development Manager
National Institute for Radioelements (IRE), Avenue de l'Esperance, B-6220 Fleurus – Belgium

ABSTRACT

IRE must ensure its key role in the global Mo-99 supply chain as one of the worldwide major radioisotope producer and is hence actively committed to reduce the proliferation risks through its medical radioisotope production conversion program based upon LEU material.

Several major milestones have been reached on different aspects of this multifaceted challenge that impacts all the radioisotopes production steps. The process demonstration without activity has been successfully achieved, allowing for the processing of irradiated targets. Subsequently, the hot commissioning is progressing well in order to demonstrate the process safety and reliability up to nominal operating conditions. In the meantime, other products such as I-131 and Xe-133 are being converted to the new LEU environment.

This presentation provides an overview of the project status and the challenges that have been overcome to enable the conversion from HEU of the IRE Mo-99 production capacity.